Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
|
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [41] Effectiveness of preoperative chemoembolization for hepatocellular carcinoma in liver transplant candidates pre- and post model for endstage liver disease.
    Taghavi, C. E.
    Meehan, M.
    Colquhoun, S. D.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S115 - S115
  • [42] SURVIVAL AND COST-EFFECTIVENESS ANALYSIS OF COMPETING STRATEGIES IN THE MANAGEMENT OF SMALL HEPATOCELLULAR CARCINOMA
    Naugler, Willscott E.
    Sonnenberg, Amnon
    HEPATOLOGY, 2010, 52 (04) : 1142A - 1142A
  • [43] Survival and Cost-Effectiveness Analysis of Competing Strategies in the Management of Small Hepatocellular Carcinoma
    Naugler, Willscott E.
    Sonnenberg, Amnon
    LIVER TRANSPLANTATION, 2010, 16 (10) : 1186 - 1194
  • [44] Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection
    Logge, Christoph
    Vettorazzi, Eik
    Fischer, Lutz
    Nashan, Bjoern
    Sterneck, Martina
    TRANSPLANT INTERNATIONAL, 2013, 26 (05) : 527 - 534
  • [45] PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival
    Nunez, Kelley G.
    Sandow, Tyler
    Fort, Daniel
    Hibino, Mina
    Wright, Paige
    Cohen, Ari J.
    Thevenot, Paul T.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (06) : 1453 - 1465
  • [46] PD-1 expression in hepatocellular carcinoma predicts liver-directed therapy response and bridge-to-transplant survival
    Kelley G. Núñez
    Tyler Sandow
    Daniel Fort
    Mina Hibino
    Paige Wright
    Ari J. Cohen
    Paul T. Thevenot
    Cancer Immunology, Immunotherapy, 2022, 71 : 1453 - 1465
  • [47] Stereotactic body radiotherapy of hepatocellular carcinoma lesions in liver transplant candidates
    Shiao, J.
    Gutierrez, A.
    Patel, A.
    Harris, A.
    Washburn, K.
    Halff, G.
    Lopera, J.
    Sharkey, F.
    Crownover, R.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S207 - S207
  • [48] DECREASING URGENCY OF LIVER TRANSPLANT CANDIDATES WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES
    Kwong, Allison J.
    Ghaziani, T. Tahereh
    Mehta, Neil
    HEPATOLOGY, 2021, 74 : 631A - 631A
  • [49] Liver-directed combined radiotherapy for downstaging of over the Milan advanced hepatocellular carcinoma converting to liver transplantation.
    Kim, Yong Tae
    Lee, Jae Geun
    Seong, Jinsil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 561 - 561
  • [50] Patterns and predictors of acute care utilization after liver-directed therapy for hepatocellular carcinoma
    Moon, Andrew
    Iloabachie, Chidi
    Power, Sydney
    Lupu, Gabriel
    Badal, Joyce
    Jiang, Yue
    Seligson, David
    Sanoff, Hanna
    Mauro, David
    Gerber, David
    Yanagihara, Ted
    Barritt, A. Sidney
    JOURNAL OF HEPATOLOGY, 2024, 80 : S403 - S403